Pangaea Oncology S.A. (PANG) - Total Liabilities
Based on the latest financial reports, Pangaea Oncology S.A. (PANG) has total liabilities worth €8.43 Million EUR (≈ $9.86 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Pangaea Oncology S.A. to track the company's year-over-year net asset growth rate.
Pangaea Oncology S.A. - Total Liabilities Trend (2013–2024)
This chart illustrates how Pangaea Oncology S.A.'s total liabilities have evolved over time, based on quarterly financial data.
Pangaea Oncology S.A. Competitors by Total Liabilities
The table below lists competitors of Pangaea Oncology S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PS Tec. Co. Ltd
KQ:002230
|
Korea | ₩38.95 Billion |
|
Nahar Industrial Enterprises Limited
NSE:NAHARINDUS
|
India | Rs6.90 Billion |
|
Dish TV India Limited
NSE:DISHTV
|
India | Rs57.40 Billion |
|
Wisekey International Holding AG
SW:WIHN
|
Switzerland | CHF53.44 Million |
|
Budi Starch & Sweetener Tbk
JK:BUDI
|
Indonesia | Rp2.33 Trillion |
|
Univastu India Limited
NSE:UNIVASTU
|
India | Rs2.18 Billion |
|
Amplia Therapeutics Ltd
AU:ATX
|
Australia | AU$1.97 Million |
|
1895 of Wisconsin Inc Bancorp
NASDAQ:BCOW
|
USA | $525.62 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Pangaea Oncology S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Pangaea Oncology S.A. worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pangaea Oncology S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pangaea Oncology S.A. (2013–2024)
The table below shows the annual total liabilities of Pangaea Oncology S.A. from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €9.57 Million ≈ $11.19 Million |
-4.55% |
| 2023-12-31 | €10.03 Million ≈ $11.72 Million |
+89.10% |
| 2022-12-31 | €5.30 Million ≈ $6.20 Million |
-21.63% |
| 2021-12-31 | €6.76 Million ≈ $7.91 Million |
-21.40% |
| 2020-12-31 | €8.61 Million ≈ $10.06 Million |
+0.50% |
| 2019-12-31 | €8.56 Million ≈ $10.01 Million |
-27.04% |
| 2018-12-31 | €11.74 Million ≈ $13.72 Million |
-15.61% |
| 2017-12-31 | €13.91 Million ≈ $16.26 Million |
+16.96% |
| 2016-12-31 | €11.89 Million ≈ $13.90 Million |
+19.45% |
| 2015-12-31 | €9.95 Million ≈ $11.64 Million |
+45.67% |
| 2014-12-31 | €6.83 Million ≈ $7.99 Million |
+45.04% |
| 2013-12-31 | €4.71 Million ≈ $5.51 Million |
-- |
About Pangaea Oncology S.A.
Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. It offers molecular diagnostics, such as mutation analysis in tissue and liquid biopsy, gene amplification and translocation testing, immunohistochemistry and fluorescence in-situ hybridization, and gene expression profiling; clinical trials; in vi… Read more